A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI /Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study
Cancer Medicine · 2026-03 · 15 (3)
DOI: 10.1002/cam4.71697 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, online erschienen am 19.03.2026. Verfasst von Wang Xicheng und 18 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Cancer Hospital and Institute, Beijing, China. Hauptthemen laut MEDLINE: Cetuximab, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pierre Fabre, Les Laboratories Pierre Fabre.
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) is a major health burden globally and in China, where 3%–5% of cases involve the BRAF V600E mutation, which is associated with aggressive disease and therefore a poor prognosis. Although the combination of encorafenib and cetuximab has demonstrated improved survival in BRAF V600E mutant metastatic CRC (mCRC), such treatments remain unavailable as chemotherapy‐free options in China.
Methods
The NAUTICAL CRC, a Phase II study in Chinese patients with BRAF V600E mutant metastatic CRC, includes a Safety Lead‐In (SLI) phase for tolerability assessment and a randomized phase comparing encorafenib/cetuximab vs. irinotecan‐based regimens, potentially bridging the treatment gap and evaluating safety, efficacy, and Quality of Life (QoL) outcomes in this Chinese population.
Results
No dose‐limiting toxicity was identified in the SLI phase ( N = 10). In the Randomized phase ( N = 97), the Doublet arm demonstrated superior progression‐free survival (PFS) of 4.2 months vs. 2.5 months in the Control arm (hazard ratio [HR]: 0.37, p = 0.0004) and longer overall survival (OS) of 11.6 months vs. 8.2 months (HR: 0.55). Treatment‐related adverse events were common but more severe in the Control arm. QoL measures consistently favored the Doublet arm, showing improved health status and reduced deterioration risk.
Conclusions
This NAUTICAL CRC Phase II study showed that the combination of encorafenib and cetuximab offers significant clinical benefits, improving PFS and OS, while providing manageable safety and important QoL advantages, making it a valuable treatment option for Chinese patients with previously treated BRAF V600E mutant mCRC. Trial Registration Clinical study registration number: NCT05004350
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University Cancer Hospital and Institute, Beijing, China.
- Sun Yat-Sen University Guangzhou, Guangzhou, China.
- Harbin Medical University Cancer Hospital Harbin, Harbin, China.
- Zhongshan Hospital Fudan University, Shanghai, China.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Fujian Cancer Hospital, Fuzhou, China.
ORCID-Profile: Liu Tianshu, Klauck Isabelle
Förderung
- Pierre Fabre
- Les Laboratories Pierre Fabre
Zitieren
APA
Xicheng, W., Yanhong, D., Yanqiao, Z., Tianshu, L., Xianglin, Y., Jianwei, Y., Tao, Z., Aimin, Z., Yu, L., Li, H., Feng, Y., Hong, Z., Yi, B., Isabelle, K., Jean-Claude, V., Mélanie, G., Angela, G., Jian, L., & Lin, S. (2026). A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI /Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71697
Vancouver
Xicheng W, Yanhong D, Yanqiao Z, Tianshu L, Xianglin Y, Jianwei Y, et al. A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI /Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71697
BibTeX
@article{Xicheng2026,
author = {Xicheng, Wang and Yanhong, Deng and Yanqiao, Zhang and Tianshu, Liu and Xianglin, Yuan and Jianwei, Yang and Tao, Zhang and Aimin, Zang and Yu, Liu and Li, Huang and Feng, Ye and Hong, Zong and Yi, Ba and Isabelle, Klauck and Jean-Claude, Vedovato and Mélanie, Groc and Angela, Guo and Jian, Li and Lin, Shen},
title = {A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI /Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cam4.71697}
}
EUVIMED